Frühere Suchanfragen

Keine früheren Suchanfragen

Suchoptionen

Nur verfügbar, wenn angemeldet.
mastodontech.de ist einer von vielen unabhängigen Mastodon-Servern, mit dem du dich im Fediverse beteiligen kannst.
Offen für alle (über 16) und bereitgestellt von Markus'Blog

Verwaltet von:

Serverstatistik:

1,5 Tsd.
aktive Profile

mastodontech.de: ÜberStatusProfilverzeichnisDatenschutzerklärung

Mastodon: ÜberApp herunterladenTastenkombinationenQuellcode anzeigenv4.4.1

#cancerresearch

7 Beiträge7 Beteiligte1 Beitrag heute
Chris Alemany🇺🇦🇨🇦🇪🇸

The man outside Espinola, Ontario.
‘I was standing here 45 years ago!”

wow.

It really is incredible the legacy Terry Fox has in all Canadian's hearts. Congratulations to his brother Darrell for completing this 45 year commemorative bike across Canada!!
#TerryFox #BikeTooter #Bike #MarathonOfHope #CancerResearch #Canada
cbc.ca/player/play/video/9.682

CBCTerry Fox’s brother finishes cross-country bike ride, at same place where Marathon of Hope startedA group of cyclists led by Darrell Fox left Stanley Park in Vancouver in early June to honour the 45th anniversary of his brother’s attempt to cross Canada on foot to raise money for cancer research. On Thursday, Darrell rolled his way to the end of his journey — the monument where Terry began his Marathon of Hope in St. John’s. The CBC’s Jeremy Eaton was there.
B_Bird

>>> Four Corners <<<

What’s behind the rise of cancer in young people?

Australians in their 30s and 40s are facing a surge in cancer and researchers are scrambling to understand why.

Aggressive cancers are hitting younger people; they’re often detected late, with devastating outcomes.

Dr Norman Swan investigates what’s behind the change.

#FourCorners #Cancer #CancerResearch #Oncology #OncoDaily #MedOnc
#Medicine #MedEd #MedicalEducation #MedicalResearch #MedNews
youtu.be/EQgP153WUUM

YouTubeWhat’s behind the rise of cancer in young people? | Four Corners DocumentaryVon ABC News In-depth
Alo Japan

alojapan.com/1314235/comparabl Comparable outcomes with 14-, 21-, or standard 28-day venetoclax in the first cycle of azacitidine–venetoclax in untreated acute myeloid leukemia: real-world experience from the Hokkaido Leukemia Net #AcuteMyeloidLeukaemia #Biomedicine #CancerResearch #general #Hematology #Hokkaido #HokkaidoNews #news #oncology #RiskFactors #北海道 Acute myeloid leukemia (AML) has a median age at diagnosis of 68 years, and many patients are deemed ineligible for…

US

europesays.com/us/32827/ AAV gene therapy for autosomal recessive deafness 9: a single-arm trial #Biomedicine #CancerResearch #ClinicalTrials #GeneTherapy #general #Genetics #InfectiousDiseases #MetabolicDiseases #MolecularMedicine #Neurosciences #Science #UnitedStates #UnitedStates #US

AAV gene therapy for autosomal recessive deafness 9: a single-arm trial
United States · AAV gene therapy for autosomal recessive deafness 9: a single-arm trial - United StatesGene therapy for congenital deafness has shown promising results in children but lacks data in older populations. We conducted a single-arm trial of adeno-associated virus (AAV)-OTOF gene therapy using the Anc80L65 capsid in ten participants with autosomal recessive deafness 9 aged 1.5 to 23.9 years at five sites in China. The primary endpoints were safety and tolerability within 5 years, and secondary endpoints assessed auditory function. Initial findings from the ten patients with 6–12 months of follow-up, including one patient who received two injections, revealed that the therapy was well tolerated, with 162 grade I/II adverse events. Decreased neutrophil percentage was the most common event (16 of 162). All ten participants had at least 6 months of follow-up and improved their pure-tone-average hearing level from baseline 106 ± 9 (mean ± s.d.) to 52 ± 30 decibels (dB). Other secondary endpoints showed similar improvements, including the average click auditory brainstem response (ABR) threshold, the tone-burst ABR threshold and the auditory steady-state response (101 ± 1 to 48 ± 26 dB, 91 ± 4 to 57 ± 19 dB and 80 ± 14 to 64 ± 21 dB, respectively). Post hoc analyses were conducted to evaluate the timecourse and factors contributing to the hearing improvement. Therapeutic effect was rapid, taking 1 month to achieve most of the overall hearing improvement. On an individual level, click and tone-burst ABR thresholds, but not the auditory steady-state response, reliably predicted the behavioral pure-tone-average thresholds after 4 months (R2 = 0.68, 0.73 and 0.17, respectively). An age-dependent therapeutic effect was observed, with optimal outcomes in 5- to 8-year-olds. These preliminary results show that AAV-OTOF was safe and well tolerated in patients ranging from toddlerhood to adulthood. The trial remains ongoing and requires extended follow-up to confirm the long-term safety and efficacy. ClinicalTrials.gov registration: NCT05901480 . Preliminary results from an investigator-initiated clinical trial showed that an AAV-OTOF gene therapy was safe and led to hearing improvements in ten patients with congenital deafness with 6–12 months of follow-up, including in a teenager and a young adult, expanding the age range from previous trials.
AngesagtLive-Feeds
Über